内科理论与实践

内科理论与实践 >

2023 , Vol. 18 >Issue 02: 121 - 123

DOI: https://doi.org/10.16138/j.1673-6087.2023.02.012

综述

新型冠状病毒疫苗诱发甲状腺疾病：挑战与应对

展开
  • 南京中医药大学附属中西医结合医院内分泌科 江苏省中医药研究院国家中医药管理局瘿病证治国家重点研究室，江苏 南京 210028

收稿日期: 2021-10-29

  网络出版日期: 2023-05-15

基金资助

国家自然科学基金项目(81800756)

收起

COVID-19 vaccine induced thyroid disease: challenges and strategies

Expand

Received date: 2021-10-29

  Online published: 2023-05-15

Fold

本文引用格式

袁力, 相萍萍, 陈国芳, 徐书杭, 刘超 . 新型冠状病毒疫苗诱发甲状腺疾病：挑战与应对[J]. 内科理论与实践, 2023 , 18(02) : 121 -123 . DOI: 10.16138/j.1673-6087.2023.02.012

参考文献

[1] Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission[J]. Lancet, 2020, 395(10223): 514-523.
[2] Ferreira LN, Pereira LN, da Fé Brás M, et al. Quality of life under the COVID-19 quarantine[J]. Qual Life Res, 2021, 30(5): 1389-1405.
[3] Saeed S, Awasthi AA, Nandi D, et al. Knowledge, attitude and practice towards COVID-19 among individuals with associated comorbidities[J]. J Med Life, 2021, 14(2): 225-237.
[4] Li MY, Li L, Zhang Y, et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues[J]. Infect Dis Poverty, 2020, 9(1): 45.
[5] Lui DTW, Lee CH, Chow WS, et al. Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19[J]. J Clin Endocrinol Metab, 2021, 106(2): e926-e935.
[6] Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19[J]. J Endocrinol Invest, 2020, 43(10): 1527-1528.
[7] Jiménez-Blanco S, Pla-Peris B, Marazuela M. COVID-19: a cause of recurrent Graves’ hyperthyroidism?[J]. J Endocrinol Invest, 2021, 44(2): 387-388.
[8] Montebello A. Recurrent Graves’ disease post SARS-CoV-2 infection[J]. BMJ Case Rep, 2021, 14(8): e244714.
[9] Pastor S, Molina á Sr, De Celis E. Thyrotoxic crisis and COVID-19 infection[J]. Cureus, 2020, 12(11): e11305.
[10] Iremli BG, ?endur SN, ünlütürk U. Three cases of sub-acute thyroiditis following SARS-CoV-2 vaccine[J]. J Clin Endocrinol Metab, 2021, 106(9): 2600-2605.
[11] Sahin Tekin M, ?ayl?soy S, Yorulmaz G. Subacute thyroiditis following COVID-19 vaccination in a 67-year-old male patient: a case report[J]. Hum Vaccin Immunother, 2021, 17(11): 4090-4092.
[12] O?uz SH, ?endur SN, Iremli BG, et al. SARS-CoV-2 vaccine-induced thyroiditis: safety of revaccinations and clinical follow-up[J]. J Clin Endocrinol Metab, 2022, 107(5): e1823-e1834.
[13] Schimmel J, Alba EL, Chen A, et al. Letter to the editor: thyroiditis and thyrotoxicosis after the SARS-CoV-2 mRNA vaccine[J]. Thyroid, 2021, 31(9): 1440.
[14] Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, et al. Two cases of Graves’ disease following SARS-CoV-2 vaccination[J]. Thyroid, 2021, 31(9): 1436-1439.
[15] Bornemann C, Woyk K, Bouter C. Case report: two cases of subacute thyroiditis following SARS-CoV-2 vaccination[J]. Front Med (Lausanne), 2021, 8: 737142.
[16] Raashid S, Khan O, Rehman Z, et al. Subacute thyroiditis after receiving inactivated virus vaccine for COVID-19[J]. J Community Hosp Intern Med Perspect, 2022, 12(2):14-17.
[17] Zettinig G, Krebs M. Two further cases of Graves’ disease following SARS-Cov-2 vaccination[J]. J Endocrinol Invest, 2022, 45(1):227-228.
[18] O?uz SH, ?endur SN, Iremli BG, et al. SARS-CoV-2 vaccine-induced thyroiditis: safety of revaccinations and clinical follow-up[J]. J Clin Endocrinol Metab, 2022, 107(5): e1823-e1834.
[19] Chattopadhyay S, Chen JY, Chen HW, et al. Nanoparticle vaccines adopting virus-like features for enhanced immune potentiation[J]. Nanotheranostics, 2017, 1(3): 244-260.
[20] Vartak A, Sucheck SJ. Recent advances in subunit vaccine carriers[J]. Vaccines (Basel), 2016, 4(2): 12.
[21] Tenforde MW, Self WH, Naioti EA, et al. Sustained effectiveness of pfizer-bioNTech and moderna vaccines against COVID-19 associated hospitalizations among adults[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(34): 1156-1162.
[22] Watad A, David P, Brown S, et al. Autoimmune/inflammatory syndrome induced by adjuvants and thyroid autoimmunity[J]. Front Endocrinol (Lausanne), 2017, 7: 150.
[23] Jara LJ, García-Collinot G, Medina G, et al. Severe manifestations of autoimmune syndrome induced by adjuvants (Shoenfeld’s syndrome)[J]. Immunol Res, 2017, 65(1): 8-16.
[24] Bragazzi NL, Hejly A, Watad A, et al. ASIA syndrome and endocrine autoimmune disorders[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(1): 101412.
[25] Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens[J]. Front Immunol, 2021, 11: 617089.
Options
文章导航

/

〈 〉